tbuckley/cabot-search huggingface dataset:
Propionate catabolism by CD-associated adherent-invasive <i>E. coli</i> counteracts its anti-inflammatory effect
Authors: Allison Agus, Damien Richard, Tiphanie Faïs, Emilie Vazeille, Mélissa Chervy, Virginie Bonnin, Guillaume Dalmasso, Jérémy Denizot, Elisabeth Billard, Richard Bonnet, Anthony Buisson, Nicolas Barnich, Julien Delmas
Journal: Gut Microbes (2021)

Crohn’s disease (CD) is a chronic and disabling inflammatory disorder of the gut that is profoundly influenced by intestinal microbiota composition, host genetics and environmental factors. Several groups worldwide have described an imbalance of the gut microbiome composition, called dysbiosis, in CD patients, with an increase in Proteobacteria and Bacteroidetes and a decrease in Firmicutes. A high prevalence of adherent-invasive Escherichia coli (AIEC) pathobionts has been identified in the intestinal mucosa of CD patients. A significant loss in the bacteria that produce short-chain fatty acids (SCFAs) with anti-inflammatory properties, such as propionate, is also a consequence of dysbiosis in CD patients. Here, the AIEC reference strain LF82 was able to degrade propionate in the gut, which was sufficient to counteract the anti-inflammatory effect of propionate both in in vitro models and in mice with DSS-induced colitis. The consumption of propionate by AIEC pathobionts leads to an increase in TNF-α production by macrophages upon infection through the bacterial methyl-citrate pathway. To induce the protective effects of SCFAs on the inflamed gut, we used a G-protein-coupled receptor 43 agonist (GPR43 agonist) that is not metabolizable by intestinal bacteria. Interestingly, this agonist showed anti-inflammatory properties and decreased the severity of colitis in AIEC-infected mice, as assessed by an improvement in the disease activity index (DAI) and a decrease in AIEC pathobiont encroachment. Taken together, these results highlight the effectiveness of GPR43 agonist treatment in the control of gut inflammation and improved our understanding of the ability of AIEC to modulate propionate availability to create an infectious niche to its advantage.
OA09.03 MESOMICS Project: Molecular Characterization of Malignant Pleural Mesothelioma Using a Multi-Omic Approach
Authors: L. Mangiante, N. Alcala, A. Di Genova, A. Sexton-Oates, C. Giacobi, N. Le-Stang, S. Boyault, F. Damiola, M. Mesobank, S. Lantuejoul, C. Caux, N. Girard, F. Galateau Salle, M. Foll, L. Fernandez-Cuesta
Journal: Journal of Thoracic Oncology (2021)
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies
Authors: Cláudia Pina Costa, João Nuno Moreira, José Manuel Sousa Lobo, Ana Catarina Silva
Journal: Acta Pharmaceutica Sinica B (2021)

The management of the central nervous system (CNS) disorders is challenging, due to the need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the various strategies that have been studied to circumvent this challenge, the use of the intranasal route to transport drugs from the nose directly to the brain has been showing promising results. In addition, the encapsulation of the drugs in lipid-based nanocarriers, such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) or nanoemulsions (NEs), can improve nose-to-brain transport by increasing the bioavailability and site-specific delivery. This review provides the state-of-the-art of
Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate
Authors: Zain Chaudhry, Marianne Shawe-Taylor, Tommy Rampling, Tim Cutfield, Gabriella Bidwell, Xin Hui S. Chan, Anna Last, Bryan Williams, Sarah Logan, Michael Marks, Hanif Esmail
Journal: Journal of Infection (2021)
P02.03 Comparison of the Efficiency of 22G Versus 25G Needle in EBUS-TBNA for Diagnosis of Lung Cancer; A Prospective Randomized, Crossover Study.
Authors: T. Sakai, H. Udagawa, K. Kirita, S. Nomura, A. Sugimoto, R. Itotani, Y. Tamiya, H. Izumi, K. Nosaki, T. Ikeda, Y. Zenke, S. Matsumoto, K. Yoh, S. Niho, G. Ishii, K. Goto
Journal: Journal of Thoracic Oncology (2021)
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review
Authors: Ghulam Rehman Mohyuddin, Kelly Koehn, Al‐Ola Abdallah, Douglas W. Sborov, S. Vincent Rajkumar, Shaji Kumar, Brian McClune
Journal: American Journal of Hematology (2021)

Surrogate endpoints are being used more frequently in randomized controlled trials, even though they do not consistently corelate with patient outcomes. We systemically evaluated the use of surrogate endpoints in multiple myeloma randomized controlled trials over the past 15 years. We searched three databases (Pubmed, Embase, Cochrane) for multiple myeloma randomized controlled trials from January 1, 2005 to December 30, 2019. The primary outcome of our study was the proportion of randomized controlled trials that used overall survival as their primary endpoint. Secondary outcomes included the use of surrogate endpoints, and trends over time, and whether they differed based on study sponsorship. We included 151 randomized controlled trials in our analysis. The primary endpoint was overall survival (OS) in 17 (11.3%) of studies, progression free survival (PFS) or event-defined endpoints in 91 studies (60.3%) and response-based endpoints in 44 studies (29.1%). Quality of life was a primary endpoint in only three studies (2%). The use of OS as a primary endpoint decreased from 28.5% of trials from 2005 to 2009 to 5.5% from 2015 to 2019. There has been a decrease in the clinically meaningful endpoint of OS over the past 15 years in multiple myeloma randomized controlled trials. Use of quality of life as a primary endpoint remains exceedingly low. It remains paramount to recognize that the use of surrogate endpoints is imperfect, and care based upon them requires constant physician and patient re-analysis.
P34.01 Utility of Assessment of the EGFR Resistance Genotype using Cell-Free DNA and CTCs from Liquid Biopsies
Authors: M. Barr, A.M. Baird, S. Gray, B. Hayes, P. Martin, S. Halliday, C. O'Brien, G. Korpanty, L. Coate, S. Cuffe, S. Finn
Journal: Journal of Thoracic Oncology (2021)
Mantle Cell Lymphoma Mimicking Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas: A Pathological Characterization (on behalf of the Fondazione Italiana Linfomi (FIL) - Postgraduate Master Course)
Authors: Sara Rattotti, Giorgio Croci, Virginia Valeria Ferretti, Lucia Morello, Dario Marino, Giuseppe Carli, Simone Ferrero, Giacomo Loseto, Jacopo Olivieri, Matteo Pelosini, Nicola Sgherza, Teresa Calimeri, Margherita Giannoccaro, Angelo Fama, Federico Mosna, Maria Chiara Tisi, Gabriella Tomei, Anna Maria Mazzone, Luca Arcaini, Francesco Zaja, Marco Paulli
Journal: Blood (2017)
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
Authors: Yahiya Y. Syed
Journal: Drugs (2021)

Ravulizumab (Ultomiris®), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has been re-engineered from eculizumab to extend its terminal elimination half-life, resulting in a more convenient maintenance dosage regimen of once every 4–8 weeks compared with once every 2–3 weeks for eculizumab. In single-arm phase 3 trials, ravulizumab resolved thrombotic microangiopathy in 54% and 78% of treatment-naïve adult and paediatric patients with aHUS, respectively, within 26 weeks. Ravulizumab was also effective in patients with postpartum aHUS and paediatric patients who responded to eculizumab and later switched to ravulizumab. Ravulizumab was generally well tolerated, with no unexpected safety events. The most common treatment-related adverse events with ravulizumab in treatment-naïve patients include headache, diarrhoea and vomiting. With its convenient once every 4–8 weeks maintenance regimen, ravulizumab is an important treatment option for aHUS in adult and paediatric patients.
P47.11 DLL-3 and ASCL-1 Expression Emerge as Promising Therapeutic Targets in High-Grade Neuroendocrine Lung Tumors: A Preliminary Study
Authors: T. Prieto, C. Machado Baldavira, A. Ab´saber, T. Takagaki, V. Capelozzi
Journal: Journal of Thoracic Oncology (2021)
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Authors: Mingming Zhang, Shan Gao, Dongjuan Yang, Yan Fang, Xiaojie Lin, Xuechao Jin, Yuli Liu, Xiu Liu, Kexin Su, Kai Shi
Journal: Acta Pharmaceutica Sinica B (2021)

The administration of nanoparticles (NPs) first faces the challenges of evading renal filtration and clearance of reticuloendothelial system (RES). After that, NPs infiltrate through the expanded endothelial space and penetrated the dense stroma of tumor microenvironment to tumor cells. As long as possible to prolong the time of NPs remaining in tumor tissue, NPs release active agent and induce pharmacological action. This review provides a comprehensive summary of the physical and chemical properties of NPs and the influence of various biological factors in tumor microenvironment, and discusses how to improve the final efficacy through adjusting the characteristics and structure of NPs. Perspectives and future directions are also provided.
P33.19 Association Between Expression of Immune Response-Related Genes and Response to Nivolumab in Metastatic Non-Small Cell Lung Cancer
Authors: A. Obuti Saito, D. Araújo, C. Sousa Filho, D. Sá, L. Walter, A.P. Silva, C. Berra, J. Germano, C. Pinto, D.M. Carraro, V.C. De Lima
Journal: Journal of Thoracic Oncology (2021)
Genetically Downregulated Interleukin-6 Signaling Is Associated With a Favorable Cardiometabolic Profile
Authors: Marios K. Georgakis, Rainer Malik, Xue Li, Dipender Gill, Michael G. Levin, Ha My T. Vy, Renae Judy, Marylyn Ritchie, Shefali S. Verma, Girish N. Nadkarni, Scott M. Damrauer, Evropi Theodoratou, Martin Dichgans
Journal: Circulation (2021)
Purinergic signaling in nervous system health and disease: Focus on pannexin 1
Authors: Juan C. Sanchez-Arias, Emma van der Slagt, Haley A. Vecchiarelli, Rebecca C. Candlish, Nicole York, Penelope A. Young, Olga Shevtsova, Afnan Juma, Marie-Ève Tremblay, Leigh Anne Swayne
Journal: Pharmacology & Therapeutics (2021)
Water exchange-assisted versus carbon dioxide-insufflated single-balloon enteroscopy: a randomized controlled trial
Authors: Shaopeng Liu, Tao Dong, Yupeng Shi, Hui Luo, Xianmin Xue, Yijin Zhu, Xiangping Wang, Biaoluo Wang, Shuhui Liang, Yanglin Pan, Xuegang Guo, Kaichun Wu
Journal: Endoscopy (2021)

Background Single-balloon enteroscopy (SBE) is a valuable but difficult modality for the diagnosis and treatment of small-bowel disease. The water exchange method has the advantage of facilitating intubation during colonoscopy. Here, we evaluated the effects of water exchange on procedure-related variables related to SBE. Methods This randomized controlled trial was conducted in a tertiary-care referral center in China. Patients due for attempted total enteroscopy were randomly allocated to undergo water exchange-assisted (water exchange group) or carbon dioxide-insufflated enteroscopy (CO2 group). All patients were planned to undergo both anterograde and retrograde procedures. The primary outcome was the total enteroscopy rate. Secondary outcomes included the maximal insertion depth, positive findings, procedural time, and adverse events. Results: In total, 110 patients were enrolled, with 55 in each group. Baseline characteristics between the two groups were comparable. Total enteroscopy was achieved in 58.2 % (32/55) of the water exchange group and 36.4 % (20/55) of the control group (P = 0.02). The mean (standard deviation) estimated intubation depth was 521.2 (101.4) cm in the water exchange group and 481.6 (95.2) cm in the CO2 group (P = 0.04). The insertion time was prolonged in the water exchange group compared with the CO2 group (178.9 [45.1] minutes vs. 154.2 [27.6] minutes; P &lt; 0.001). Endoscopic findings and adverse events were comparable between the two groups. Conclusions: The water exchange method improved the total enteroscopy rate and increased the intubation depth during SBE. The use of water exchange did not increase the complications of enteroscopy.
P37.29 Clinical Characteristics that Affect the Success Rate of BRAF-V600E Oncomine Dx Target Test
Authors: Y. Sato, S. Hara, Y. Shima, Y. Shimada, M. Osaki, A. Matsunashi, R. Hirabayashi, K. Nagata, A. Nakagawa, R. Tachikawa, K. Tomii
Journal: Journal of Thoracic Oncology (2021)
Plasminogen: an enigmatic zymogen
Authors: Charithani B. Keragala, Robert L. Medcalf
Journal: Blood (2021)

Abstract Plasminogen is an abundant plasma protein that exists in various zymogenic forms. Plasmin, the proteolytically active form of plasminogen, is known for its essential role in fibrinolysis. To date, therapeutic targeting of the fibrinolytic system has been for 2 purposes: to promote plasmin generation for thromboembolic conditions or to stop plasmin to reduce bleeding. However, plasmin and plasminogen serve other important functions, some of which are unrelated to fibrin removal. Indeed, for &amp;gt;40 years, the antifibrinolytic agent tranexamic acid has been administered for its serendipitously discovered skin-whitening properties. Plasmin also plays an important role in the removal of misfolded/aggregated proteins and can trigger other enzymatic cascades, including complement. In addition, plasminogen, via binding to one of its dozen cell surface receptors, can modulate cell behavior and further influence immune and inflammatory processes. Plasminogen administration itself has been reported to improve thrombolysis and to accelerate wound repair. Although many of these more recent findings have been derived from in vitro or animal studies, the use of antifibrinolytic agents to reduce bleeding in humans has revealed additional clinically relevant consequences, particularly in relation to reducing infection risk that is independent of its hemostatic effects. The finding that many viruses harness the host plasminogen to aid infectivity has suggested that antifibrinolytic agents may have antiviral benefits. Here, we review the broadening role of the plasminogen-activating system in physiology and pathophysiology and how manipulation of this system may be harnessed for benefits unrelated to its conventional application in thrombosis and hemostasis.
P04.07 Long-term Postoperative Prognosis of Adenocarcinoma in Situ and Minimally Invasive Adenocarcinoma of Lung
Authors: M. Yotsukura, N. Motoi, Y. Yoshida, K. Nakagawa, Y. Yatabe, S. Watanabe
Journal: Journal of Thoracic Oncology (2021)
Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells
Authors: Vaclava Polivkova, Adela Benesova, Hana Zizkova, Jitka Koblihova, Nikola Curik, Eliska Motlova, Hana Klamova, Cyril Salek, Katerina Machova Polakova
Journal: Leukemia (2021)
Abstract 14923: Alternative Autophagy Protects the Heart Against High Fat Diet-Induced Diabetic Cardiomyopathy
Authors: Mingming Tong, Peiyong Zhai, Junichi Sadoshima
Journal: Circulation (2019)

Chronic consumption of high fat diet (HFD) induces accumulation of dysfunctional mitochondria, which in turn induces cardiac dysfunction. Clearance of damaged mitochondria by mitophagy is essential...
P76.71 RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations
Authors: S. Ohara, T. Mitsudomi, K. Suda, T. Fujino, T. Koga, J. Soh, T. Takemoto, M. Shimoji, M. Nishino, M. Chiba, A. Hamada
Journal: Journal of Thoracic Oncology (2021)
P35.14 NGS-Based Molecular Profiling of ‘Quadruple-Negative’ (EGFR/KRAS/ALK/ROS1) Advanced Non-Small-Cell Lung Cancer (aNSCLC).
Authors: S. Pilotto, I. Sperduti, M. Sposito, M. Casali, M.G. Ferrara, L. Calvetti, A. Veccia, A. Bonato, G. Sartori, L. Belluomini, E. Vita, L. Cucciniello, N. Inzerilli, H. Soto Parra, G. Aprile, O. Caffo, A. Scarpa, G. Tortora, E. Bria, M. Milella
Journal: Journal of Thoracic Oncology (2021)
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
Authors: François Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte, Jean-Marie Certoux, Philippe Souque, Francine Garnache, Olivier Adotevi, Pierre Langlade-Demoyen, Maria Loustau, Julien Caumartin
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific antigen (TSA), and immunosuppressive tumor microenvironment sometimes caused by the tumorous expression of immune checkpoints (ICPs) such as HLA-G. Indeed, HLA-G is remarkable because it is both a potent ICP and a TSA. HLA-G tumor expression causes immune escape by impairing innate and adaptive immune responses and by inducing a suppressive microenvironment. Yet, to date, no immunotherapy targets it. Methods We have developed two anti-HLA-G third-generation CARs based on new anti-HLA-G monoclonal antibodies. Results Anti-HLA-G CAR-T cells were specific for immunosuppressive HLA-G isoforms. HLA-G-activated CAR-T cells polarized toward T helper 1, and became cytotoxic against HLA-G + tumor cells. In vivo, anti-HLA-G CAR-T cells were able to control and eliminate HLA-G + tumor cells. The interaction of tumor-HLA-G with interleukin (IL)T2-expressing T cells is known to result in effector T cell functional inhibition, but anti-HLA-G CAR-T cells were insensitive to this inhibition and still exerted their function even when expressing ILT2. Lastly, we show that anti-HLA-G CAR-T cells differentiated into long-term memory effector cells, and seemed not to lose function even after repeated stimulation by HLA-G-expressing tumor cells. Conclusion We report for the first time that HLA-G, which is both a TSA and an ICP, constitutes a valid target for CAR-T cell therapy to specifically target and eliminate both tumor cells and HLA-G + suppressive cells.
FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
Authors: R. Veillon, H. Sakai, X. Le, E. Felip, M.C. Garassino, A. Cortot, E. Smit, K. Park, F. Griesinger, C. Britschgi, Y. Wu, K. Berghoff, G. Otto, R. Bruns, P. Paik
Journal: Journal of Thoracic Oncology (2021)
MA06.09 Preliminary Safety, Efficacy Results of KN046 (Bispecific Anti-PD-L1/CTLA4) in Subjects With Rare Thoracic Tumors
Authors: G. Richardson, G. Kichenadasse, V. Ganju, J. Xu, H. Van, P. Kong, F. Yang, Y. Wei, Y. Lu, K. Guo, L. Donato, T. Xu, J. Coward
Journal: Journal of Thoracic Oncology (2021)
Utility of mismatch repair protein expression screening via an endoscopic ultrasound assessment of treatment-naive pancreas ductal adenocarcinoma
Authors: Ana Garcia Garcia de Paredes, Rondell P Graham, Michael J Levy, Robert R McWilliams, Elizabeth Rajan, Lizhi Zhang, Ferga C Gleeson
Journal: Gut (2021)

We read with great interest the recent articles by Luchini et al 1 2 and Grant et al 3 highlighting the low prevalence (1%–2%) of mismatch repair deficient pancreatic ductal adenocarcinoma (dMMR PDAC) and offering further knowledge pertaining to the molecular spectrum of this disease subtype. A plea was raised to augment translational and clinical research efforts to improve our understanding of dMMR PDAC.

However, from a practical perspective, only 20% of patients with PDAC reach surgical oncologic resection.4 These resection specimens have served as the source of prior dMMR PDAC analysis. Following the United States Food and Drug Administration approval of pembrolizumab as the first cancer therapy targeting a specific molecular signature, we identified a dMMR prevalence of 3% in a small retrospective cohort of archived pancreas endoscopic ultrasound fine-needle biopsy (EUS FNB) specimens.5 We recently completed an 18-month prospective evaluation of 218 consecutive treatment-naive PDAC patients diagnosed by EUS (fine-needle aspiration: 112 (51.4%), FNB: 91 (41.7%) or both: 15 (6.9%)) for MMR screening as a companion diagnostic test (table 1). A specimen adequate for ancillary studies was acquired in 193 (88.5%) patients …
Dense Circuit Reconstruction to Understand Neuronal Computation: Focus on Zebrafish
Authors: Rainer W. Friedrich, Adrian A. Wanner
Journal: Annual Review of Neuroscience (2021)

The dense reconstruction of neuronal wiring diagrams from volumetric electron microscopy data has the potential to generate fundamentally new insights into mechanisms of information processing and storage in neuronal circuits. Zebrafish provide unique opportunities for dynamical connectomics approaches that combine reconstructions of wiring diagrams with measurements of neuronal population activity and behavior. Such approaches have the power to reveal higher-order structure in wiring diagrams that cannot be detected by sparse sampling of connectivity and that is essential for neuronal computations. In the brain stem, recurrently connected neuronal modules were identified that can account for slow, low-dimensional dynamics in an integrator circuit. In the spinal cord, connectivity specifies functional differences between premotor interneurons. In the olfactory bulb, tuning-dependent connectivity implements a whitening transformation that is based on the selective suppression of responses to overrepresented stimulus features. These findings illustrate the potential of dynamical connectomics in zebrafish to analyze the circuit mechanisms underlying higher-order neuronal computations.
Dupilumab rapidly improves sense of smell in patients with severe chronic rhinosinusitis with nasal polyps : pooled results from the SINUS-24 and SINUS-52 phase 3 studies
Authors: J. Mullol, Claus Bachert, M. Desrosiers, J. K. Han, R. Jankowski, N. Daizadeh, N. Amin, L. P. Mannent, A. H. Khan, S. Kamat
Journal: Allergy (2020)
Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases
Authors: Samih H. Nasr, Mary E. Fidler, Samar M. Said, Justin W. Koepplin, Jamie M. Altamirano-Alonso, Nelson Leung
Journal: Kidney International (2021)
HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)
Authors: Kirsten Stuber, Habte A. Yimer, Karin Choquette, Sudhir Manda, Jennifer Clayton, Saulius Girnius, Joshua Richter, Presley Whidden, Kimberly Bogard, Dasha Cherepanov, Stephen J. Noga
Journal: Journal of the National Comprehensive Cancer Network (2021)

"HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)" published on 17 Mar 2021 by National Comprehensive Cancer Network.
P61.01 Imipramine Blue (IP) plus MET Tyrosine Kinase Inhibitors (TKI) Suppress Lung Adenocarcinoma (LUAD) KRAS Mutation Tumor Growth
Authors: R. Rosell, I. Chaib, M. Ito, F. Laguia, D. Lligé, S. Fancelli, L. Pudelko, C. Pedraz-Valdunciel, M. Filipska, J. Bracht, J. Arbiser, J. Codony-Servat, A. Giménez-Capitán, S. Viteri, M. González-Cao, A. Aguilar, M.A. Molina-Vila
Journal: Journal of Thoracic Oncology (2021)
OA03.05 Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Authors: A. Nakamura, Y. Yoneshima, S. Morita, M. Ando, S. Iwasawa, H. Yoshioka, Y. Goto, M. Takeshita, T. Harada, K. Hirano, T. Oguri, M. Kondo, S. Miura, Y. Hosomi, T. Kato, T. Kubo, J. Kishimoto, N. Yamamoto, Y. Nakanishi, I. Okamoto
Journal: Journal of Thoracic Oncology (2021)